American College of Cardiology

GRUNDY ET AL., Assessment of Cardiovascular Risk
J Am Coll Cardiol 1999;34:1348--59

AHA/ACC Scientific Statement: Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations

A Statement for Healthcare Professionals From the American Heart Association and the American College of Cardiology

References

2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.

3. Eckel RH. Obesity and heart disease: a statement for healthcare profes- sionals from the Nutrition Committee, American Heart Association. Circulation 1997;96:3248-50.

4. Fletcher GF, Balady G, Blair SN, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans: a statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996;94:857-62.

5. NHLBI Obesity Education Initiative Expert Panel. Clinical Guidelines on Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1998.

6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II). Circulation. 1994; 89:1329-445.

7. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. NIH publication 98-4080.

8. American Diabetes Association. Clinical practice recommendations. Diabetes Care. 1999;22 Suppl 1:S1-S114.

9. Wood D, De Backer G, Faergemann O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommen- dations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-503.

10. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coro- nary heart disease: guidance from Framingham: a statement for healthcare professionals from the American Heart Association's Task Force on Risk Reduction. Circulation 1998;97:1876-87.

11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.

12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301-7.

13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol And Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.

14. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

15. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cho- lesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279: 1615-22.

16. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256: 2823-8.

17. Grundy SM, Wilhelmsen L, Rose R, Campbell RWF, Assman G. Cor- onary heart disease in high-risk populations: lessons from Finland. Eur Heart J 1990;11:462-71.

18. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-202.

19. Epstein FH, Ostrander LD Jr, Johnson BC, et al. Epidemiological studies of cardiovascular disease in a total community: Tecumseh, Michigan. Ann Intern Med 1965;62:1170-87.

20. Paul O, Lepper MH, Phelan WH, et al. A longitudinal study of coronary heart disease. Circulation 1963;28:20-31.

21. Stamler J, Lindberg HA, Berkson DM, Shaffer A, Miller W, Poindexter A. Prevalence and incidence of coronary heart disease in strata of the labor force of a Chicago industrial corporation. J Chronic Dis 1960;11: 405-20.

22. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the Pooling Project: the Pooling Project Research Group. J Chronic Dis 1978;31:201-306.

23. Keys A, ed. Coronary heart disease in seven countries. Circulation 1970;41 Suppl 4:1-211.

24. Marmot MG, Syme SL, Kagan A, Kato H, Cohen JB, Belsky J. Epide- miologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: prevalence of coronary and hypertensive heart disease and associated risk factors. Am J Epidemiol 1975;102:514-25.

25. Worth RM, Kato H, Rhoads GG, Kagan K, Syme SL. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California: mortality. Am J Epidemiol 1975;102: 481-90.

26. Fraser GE. Determinants of ischemic heart disease in Seventh-Day Adventists: a review. Am J Clin Nutr 1988;48:833-6.

27. Wilson PWF, Abbott RD, D'Agostino RB Jr, Rodriguez BL, Curb JD, Burns JA. Prediction of coronary heart disease in Japanese-American men (abstr). Circulation 1998;98 Suppl I:I-323.

28. Karter AJ, Gazzaniga JM, Cohen RD, Casper ML, Davis BD, Kaplan GA. Ischemic heart disease and stroke mortality in African-American, Hispanic, and non-Hispanic white men and women, 1985 to 1991. West J Med 1998;169:139-45.

29. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coro- nary risk profile: a statement for health professionals. Circulation 1991; 83:356-62.

30. Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovascular diseases: a statement for healthcare professionals from the Task Force on Risk Reduction, American Heart Association Science Advisory and Coordinating Committee. Circulation 1997;95:2329-31.

31. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1998;96:3243-7.

32. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw Hill, 1995:1981-2030.

33. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ. Coronary artery disease in IDDM: gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol 1996;16:720-6.

34. Wilson PW. Diabetes mellitus and coronary heart disease. Am J Kidney Dis 1998;32:S89-S100.

35. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.

36. Stone PH, Muller JE, Hartwell T, et al., and the MILIS Study Group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prog- nosis: the MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.

37. Management of dyslipidemia in adults with diabetes: American Diabetes Association. Diabetes Care 1998;21:179-82.

38. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983;71:1854-66.

39. Emond M, Mock MB, Davis KB, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-57.

40. Storstein O, Enge I, Erikssen EJ, Thaulow E. Natural history of coronary artery disease studied by coronary arteriography: a seven-year study of 795 patients. Acta Med Scand 1981;210:53-8.

41. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic under- estimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994;308:363-6.

42. Krieger DR, Landsberg L. Mechanisms in obesity-related hypertension: role of insulin and catecholamines. Am J Hypertens 1988;1:84-90.

43. Denke MA, Sempos CT, Grundy SM. Excess body weight: an under- recognized contributor to dyslipidemia in white American women. Arch Intern Med 1994;154:401-10.

44. Denke MA, Sempos CT, Grundy SM. Excess body weight: an under- recognized contributor to high blood cholesterol levels in white American men. Arch Intern Med 1993;153:1093-103.

45. Tchernof A, Lamarche B, Prud'Homme D, et al. The dense LDL phenotype: association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996;19:629-37.

46. Bogardus C, Lillioja S, Mott D, Reaven GR, Kashiwagi A, Foley JE. Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians. J Clin Invest 1984;73: 800-5.

47. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Rela- tionship of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96:88-98.

48. Mykkanen L, Ronnemaa T, Marniemi J, Haffner SM, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994;14:1264-71.

49. Giltay EJ, Elbers JM, Gooren LJ, Emeis JJ, Kooistra T, Asscheman H, Stehouwer CD. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998; 18:1716-22.

50. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995;141:1117-27.

51. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med 1995;333:677-85.

52. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Overweight and mortality in Mexican Americans. Int J Obes 1990;14:623-9.

53. Pettitt DJ, Lisse JR, Knowler WC, Bennett PH. Mortality as a function of obesity and diabetes mellitus. Am J Epidemiol 1982;115:359-66.

54. Stevens J, Keil JE, Rust PF, Tyroler HA, Davis CE, Gazes PC. Body mass index and body girths as predictors of mortality in black and white women. Arch Intern Med 1992;152:1257-62.

55. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: Department of Health and Human Services, Centers for Disease Control and Pre- vention, National Center for Chronic Disease Prevention and Health Promotion; 1996.

56. Kannel WB, Sorlie P. Some health benefits of physical activity: the Framingham Study. Arch Intern Med 1979;139:857-61.

57. Kannel WB, Wilson PWF, Blair SN. Epidemiological assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985;109:876-85.

58. Kannel WB, Belanger A, D'Agostino R, Israel I. Physical activity and physical demand on the job and risk of cardiovascular disease and death: the Framingham Study. Am Heart J 1986;112:820-5.

59. Dannenberg AL, Keller JB, Wilson PW, Castelli WP. Leisure time physical activity in the Framingham Offspring Study: description, seasonal variation, and risk factor correlates. Am J Epidemiol 1989;129: 76-88.

60. Rodriguez BL, Curb JD, Burchfiel CM, et al. Physical activity and 23-year incidence of coronary heart disease morbidity and mortality among middle-aged men: the Honolulu Heart Program. Circulation 1994;89:2540-4.

61. Blair SN. Physical activity, fitness, and coronary heart disease. In: Bouchard C, Shephard RJ, Stephens T, editors. Physical Activity, Fitness and Health: International Proceedings and Consensus Statement. Champaign: Human Kinetics, 1994:579-90.

62. Blair SN, Kohl HW III, Barlow CE, Paffenbarger RS Jr, Gibbons LW, Macera CA. Changes in physical fitness and all-cause mortality: a prospective study of healthy and unhealthy men. JAMA 1995;273: 1093-8.

63. Fletcher GF. How to implement physical activity in primary and sec- ondary prevention: a statement for healthcare professionals from the Task Force on Risk Reduction, American Heart Association. Circulation 1997;96:355-7.

64. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 1990;120:963-9.

65. Christensen AJ, Smith TW. Cynical hostility and cardiovascular reac- tivity during self-disclosure. Psychosom Med 1993;55:193-202.

66. King KB. Psychologic and social aspects of cardiovascular disease. Ann Behav Med 1997;19:264-70.

67. Eaker ED. Psychosocial risk factors for coronary heart disease in women. Cardiol Clin 1998;16:103-11.

68. Williams R, Bhopal R, Hunt K. Coronary risk in a British Punjabi population: a comparative profile of non-biochemical factors. Int J Epidemiol 1994;23:28-37.

69. Pugh RN, Hossain MM, Malik M, El Mugamer IT, White MA. Arabian Peninsula men tend to insulin resistance and cardiovascular risk seen in South Asians. Trop Med Int Health 1998;3:89-94.

70. Seedat YK, Mayet FG. Risk factors leading to coronary heart disease among the black, Indian and white peoples of Durban. J Hum Hypertens 1996;10 Suppl 3:S93-S94.

71. Goff DC Jr, Ramsey DJ, Labarthe DR, Nichaman MZ. Greater case- fatality after myocardial infarction among Mexican Americans and women than among non-Hispanic whites and men: the Corpus Christi Heart Project. Am J Epidemiol 1994;139:474-83.

72. Goff DC, Nichaman MZ, Chan W, Ramsey DJ, Labarthe DR, Ortiz C. Greater incidence of hospitalized myocardial infarction among Mexican Americans than non-Hispanic whites: the Corpus Christi Heart Project, 1988-1992. Circulation 1997;95:1433-40.

73. Keys A, Menotti A, Aravanis C, et al. The Seven Countries Study: 2,289 deaths in 15 years. Prev Med 1984;13:141-54.

74. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7.

75. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.

76. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.

77. Assman G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19 Suppl M:M8-M14.

78. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18B-25B.

79. Manninen V, Huttunen JK, Heinonen OP, Tenkanen L, Frick MH. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study. Am J Cardiol 1989;63:42H-47H.

80. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study to combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223: 405-18.

81. Kaplinsky E. The Bezabifrate Infarction Prevention Study. Paper pre- sented at: Annual Meeting of the European Society of Cardiology; August 1998; Vienna, Austria.

82. Krauss RM. Dense low density lipoproteins and coronary artery disease. Am J Cardiol 1995;75:53B-57B.

83. Gardner CD, Fortmann SP, Krauss RM. Association of small low- density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81.

84. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ath- erosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.

85. Reaven GM. Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia, and coronary heart disease. Am Heart J 1991;121:1283-8.

86. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.

87. Stern MP. Impaired glucose tolerance: risk factor or diagnostic category. In: LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott-Raven Publishers, 1996:467-74.

88. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979;59:8-13.

89. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 1979; 2:120-6.

90. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Fra- mingham Study. JAMA 1979;241:2035-8.

91. Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue. J Intern Med 1998;243:265-74.

92. Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin-resistance state. Diabetes 1994;43:411-7.

93. Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Me- tabolism 1997;46:40-3.

94. Pi-Sunyer FX. Short-term medical benefits and adverse effects of weight loss. Ann Intern Med 1993;119:722-6.

95. Perseghin G, Price TB, Petersen KF, et al. Increased glucose transport- phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N Engl J Med 1996;335:1357-62.

96. Beresford SA, Boushey CJ. Homocysteine, folic acid, and cardiovascu- lar disease risk. In: Bendich A, Deckelbaum RJ, editors. Preventive Nutrition: The Comprehensive Guide for Health Professionals. Totowa, NJ: Humana Press, 1997.

97. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277:1775-81.

98. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.

99. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999;99:178-82.

100. Landgren F, Israelsson B, Lindgren A, Hultberg B, Andersson A, Brattstrom L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med 1995;237: 381-8.

101. Ubbink JB, Becker PJ, Vermaak WJ, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995;41:1033-7.

102. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-26.

103. Bostom AG, Cupples A, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a pro- spective study. JAMA 1996;276:544-8.

104. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270: 2195-9.

105. Moliterno DJ, Jokinen EV, Miserez AR, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995;15:850-5.

106. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998;19 Suppl H:H- 11-H-17.

107. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995;16 Suppl A:A-31-A-34.

108. Rigotti NA, Pasternak RC. Cigarette smoking and coronary heart disease: risks and management. Cardiol Clin 1996;14:51-68.

109. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Eval- uation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998;32:35-41.

110. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (moni- toring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.

111. Eda S, Kaufmann J, Roos W, Pohl S. Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range. J Clin Lab Anal 1998;12:137-44.

112. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.

113. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.

114. Pyorala K, Pederson TR, Kjeksyhus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.

115. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myo- cardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial: the CARE Investigators. Circulation 1998;98: 2513-9.

Copyright © 2000 by The American Heart Association, Inc. and
The American College of Cardiology